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Abstract
Recovery from blood loss requires a greatly enhanced supply of iron to support expanded 
erythropoiesis. After hemorrhage, suppression of the iron-regulatory hormone hepcidin allows 
increased iron absorption and mobilization from stores. We identified a new hormone, 
erythroferrone (ERFE), which mediates hepcidin suppression during stress erythropoiesis. ERFE 
is produced by erythroblasts in response to erythropoietin. ERFE-deficient mice fail to suppress 
hepcidin rapidly after hemorrhage and exhibit a delay in recovery from blood loss. ERFE 
expression is greatly increased in murine HbbTh3/+ thalassemia intermedia where it contributes to 
the suppression of hepcidin and systemic iron overload characteristic of this disease.
INTRODUCTION
Iron is an essential component of heme and hemoglobin. The production of functional 
erythrocytes therefore requires the timely delivery of sufficient iron to erythroid precursors. 
The iron supply to the marrow comes under particular strain after hemorrhage, hemolysis 
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and other conditions that trigger stress erythropoiesis. Both the absorption of dietary iron 
and the release of iron from stores are increased as erythropoiesis intensifies but the 
mechanism through which erythropoiesis modulates iron homeostasis, historically referred 
to as the “erythroid regulator”, is not understood1. After the loss of erythrocytes from 
hemorrhage or hemolysis, critical signals facilitating the provision of iron for restorative 
erythropoiesis would be expected to act within hours, as rapid recovery of red cell mass and 
oxygen carrying capacity confers obvious evolutionary advantages.
The liver-produced hormone hepcidin is the main circulating regulator of iron absorption 
and tissue distribution2. Hepcidin controls the major flows of iron into plasma: absorption of 
dietary iron in intestine, recycling of iron by macrophages which phagocytose old 
erythrocytes and other cells, and mobilization of stored iron from hepatocytes. Iron is 
exported from these tissues into plasma through ferroportin, the sole known cellular iron 
exporter and the hepcidin receptor. Hepcidin causes endocytosis and degradation of 
ferroportin, leading to the retention of iron in iron-exporting cells and decreased flow of iron 
into plasma. In turn, hepcidin production is transcriptionally regulated in response to 
changes in circulating iron concentration, iron stores, or the development of inflammation 
and iron-restricted erythropoiesis2.
In view of the central role of hepcidin in systemic iron homeostasis, the putative erythroid 
regulators could facilitate iron delivery to the marrow by decreasing blood hepcidin 
concentrations, and thereby allowing increased iron absorption and the release of iron from 
stores into blood plasma. Indeed, anemia induced by hemorrhage or hemolysis decreased 
hepcidin in mice3, and the suppressive effect of anemia on hepcidin depended on 
erythropoietin and functional bone marrow4, 5. In normal volunteers, the administration of 
erythropoietin was sufficient to lower serum hepcidin profoundly within less than 1 day in 
the absence of any significant changes in serum iron6.
In contrast to their adaptive role in the recovery from blood loss, erythroid regulators may 
act pathologically to mediate iron overload and its severe clinical complications in inherited 
anemias with ineffective erythropoiesis such as β-thalassemia and congenital 
dyserythropoietic anemia. This mechanism may be particularly prominent in untransfused 
patients in whom iron overload develops because of the pathological suppression of 
hepcidin synthesis and the resulting hyperabsorption of dietary iron7. Even in transfused 
patients, in whom ineffective erythropoietic activity is partially ameliorated, erythroid 
regulators and associated hepcidin suppression may contribute to the iron overload, 
particularly late during the intervals between transfusions. Growth differentiation factor 15 
(GDF15) and twisted-gastrulation 1 (TWSG1) are bone morphogenetic protein family 
members that have been proposed as pathological suppressors of hepcidin in 
thalassemia 8, 9. However, the evidence for the pathogenic role of these mediators in iron-
loading anemias is not definitive and recent studies argue against their contribution in 
physiological hepcidin suppression after hemorrhage10–12. In the current study, we describe 
the identification of a new erythroid regulator essential for early suppression of hepcidin 
after erythropoietic stimulation.
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RESULTS
Suppression of hepcidin by erythropoietic stimulation
We first examined the time-course of hepatic hepcidin response to increased erythropoietic 
activity. Six week-old C57BL/6 males were phlebotomized 500 μL or treated with 200 units 
of erythropoietin (EPO). Hepcidin mRNA levels were reduced within 9 hours after 
erythropoietic stimulation, reached a nadir 10-fold suppression 15 hours after phlebotomy or 
EPO treatment and remained partially decreased even at 48 hours (Fig. 1A). Serum hepcidin 
concentrations were concordant with the mRNA data (Fig. 1B). The suppression occurred 
with a similar timing in mice as had been reported in human volunteers (between 9–24 hours 
after EPO injection) 6 thus we focused on the early mechanism of hepcidin suppression, 
active in the first 24 hours after hemorrhage. As was the case in the human study, no 
significant changes in serum iron concentration were observed after either stimulus 
(Supplementary Fig. 1).
BMP/Smad signaling pathway is a major regulator of hepcidin transcription13, 14, and is 
involved in iron-dependent modulation of hepcidin expression. To assess if the hepatic 
BMP/Smad signaling is decreased in response to erythropoietic stimulation, we measured 
Smad5 phosphorylation in the livers of phlebotomized or EPO-treated mice 15 hours after 
the stimulus. Smad5 phosphorylation was not significantly decreased in either 
phlebotomized (Supplementary Fig. 2A, B) or EPO-treated mice (Supplementary Fig. 2C, 
D) compared to control mice. We also examined Id1 mRNA, a well-established marker of 
BMP/Smad activation15. In contrast to the profound suppression of hepcidin, only a mild 
decrease in Id1 mRNA levels was observed 9 and 15 hours after phlebotomy but no changes 
were observed 12 hours after bleeding or at any time after EPO treatment (Supplementary 
Fig. 2E). Together, these data suggest that hepcidin suppression by increased erythropoietic 
activity occurs independently of the canonical BMP/Smad signaling pathway. Moreover, 
using mice deficient in transferrin receptor 2 (TfR2) or hemojuvelin (HJV), important 
regulators of hepcidin response to iron and modulators of BMP signaling, we showed that 
neither TfR2 nor HJV were required for erythropoietic suppression of hepcidin 
(Supplementary Fig. 3A, B). Additionally, we stimulated the BMP pathway in WT mice by 
administering parenteral iron to cause extreme iron overload (liver iron content in 
Supplementary Fig. 3C). Even in these mice with very high hepcidin baseline, phlebotomy 
acutely suppressed hepcidin (Supplementary Fig. 3B). Thus, the erythropoietic suppression 
of hepcidin appears to act independently of the BMP pathway.
Bone marrow gene-expression profiling
Guided by previous studies4, 5 suggesting that the erythroid regulator may be secreted by the 
bone marrow after erythropoietic stimulation, we studied mRNA changes in the mouse 
marrow 0–48 hours after bleeding, using Affymetrix gene chip-based expression profiling. 
No changes were observed in Gdf15 and Twsg1 mRNAs, which encode previously proposed 
candidates for the erythroid regulator. We focused our attention on erythroid-specific 
transcripts encoding secreted proteins, with mRNA expression that was induced prior to, and 
was maintained at high levels during the suppression of hepatic hepcidin mRNA expression. 
A previously uncharacterized transcript, listed in the databases as Fam132b, fit these 
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criteria: it was predicted to encode a secreted protein and was highly induced within 4 hours 
after bleeding, prior to hepcidin suppression. After its further characterization, we named 
this factor “erythroferrone” (ERFE), to denote its function as an erythroid hormone acting 
on iron metabolism. In the meantime, the protein encoded by Fam132b was also described 
by others as myonectin or CTRP1516, a member of the C1q/TNF-related protein family 
(CTRP). Pending definitive resolution of the nomenclature, we will refer to erythroferrone 
protein as ERFE and to the corresponding mRNA and gene as Fam132b.
Validation studies by qRT-PCR demonstrated that the Fam132b mRNA was induced in the 
bone marrow already within 4 hours after phlebotomy and reached maximal induction of 
over 30-fold by 9 hours (Fig. 2A) before decreasing toward baseline after 24–48 hours. 
Fam132b mRNA expression after phlebotomy mirrored serum erythropoietin concentrations 
(Supplementary Fig. 4). EPO treatment resulted in a similar (but more rapid) induction of 
Fam132b mRNA suggesting that the gene encoding ERFE is EPO-responsive (Fig. 2A). In 
the absence of any stimulation, Fam132b mRNA in the spleen was expressed at a very low 
level but was induced 8–10 fold after phlebotomy or EPO injection (Fig. 2B) supporting its 
role in stress erythropoiesis. The induction of Fam132b mRNA by phlebotomy was not 
affected by modulation of BMP signaling through iron loading or genetic ablation of TfR2 or 
hemojuvelin (Supplementary Figure 3D).
ERFE is produced by erythroblasts
We next assessed tissue-specific expression of Fam132b mRNA from control and EPO-
treated 6 week-old male wild-type mice. At baseline, the highest Fam132b expression was 
detected in the colon, the duodenum, the muscle, the bone marrow and the testis (Fig. 3A). 
After EPO stimulation, however, Fam132b induction was observed only in the bone marrow 
and the spleen, the erythropoietic organs of the adult mouse. Moreover, EPO-stimulated 
marrow became the organ with the highest expression of Fam132b mRNA supporting the 
idea that it may have erythroid-specific function. To examine Fam132b expression across 
the stages of erythroid differentiation, we sorted by flow cytometry the erythroblast 
population from the marrow of control or phlebotomized (15 hours time-point) wild-type 
mice. Erythroblasts populations were separated based on their size and the expression of the 
erythroid markers Ter119 and transferrin receptor 1 (TfR1) into pro-erythroblasts, 
basophilic, polychromatic and orthochromatic erythroblasts as previously described17. 
Fam132b mRNA was increased after phlebotomy in all four populations of erythroid 
precursors, with highest expression detected in basophilic and polychromatic erythroblasts 
(Fig. 3B).
The cDNA sequence available for human FAM132B in public databases (GenBank 
XM_001714385.4) had been predicted from the genomic sequence and was not validated by 
mRNA sequencing. We performed 5′ RACE on total RNA from human fetal liver 
erythroblasts and cloned the dominant cDNA sequence which differed from the predicted 
sequence at the 5′ terminus, including the codons for the first 70 amino acids. With this 
change, the human and mouse ERFE protein sequences contain 354 and 340 amino acid 
residues respectively and are 71% identical. The C-terminal half of the predicted proteins 
shows even higher identity and encodes a TNF-α-like domain16. In human erythroblasts 
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isolated from fetal liver or adult bone marrow, FAM132B mRNA expression was also 
strongly induced by erythropoietin (>16-fold) (Supplementary Fig. 5).
Binding of EPO to its receptor is known to activate the Jak2-Stat5 signaling pathway 
necessary for stress erythropoiesis18. Because in silico analysis of the murine Fam132b 
promoter spanning 3000bp upstream of the transcription initiation site revealed multiple 
putative Stat5 binding elements (MatInspector, Genomatix Software) (Supplementary Table 
1), we explored the involvement of this pathway in ERFE regulation. Treatment of total 
mouse bone marrow cells with two chemically unrelated Stat5 inhibitors (pimozide or N′-
((4-Oxo-4H-chromen-3-yl)methylene)nicotinohydrazide) prior to a 15 hours incubation with 
EPO inhibited Fam132b mRNA stimulation (Fig. 3C). Thus, EPO regulates Fam132b 
expression in erythroblasts through the stress erythropoiesis-related Jak2/Stat5 signaling 
pathway.
In contrast, we found no effect of hypoxia-related or systemic inflammatory signaling on 
Fam132b mRNA expression in the marrow. Treatment of mouse marrow cells in vitro with 
dimethyloxalylglycine (DMOG), an inhibitor of oxygen-sensing prolyl hydroxylases that 
mediate hypoxia-related signaling, had no effect on Fam132b mRNA expression even 
though it strongly induced Vegfα mRNA (Supplementary Fig. 6). Bone marrow Fam132b 
mRNA concentrations were also unresponsive to an acute inflammatory stimulus in vivo. 
Four hours after lipopolysaccharide injection into mice, TNFα, IL6 and hepcidin mRNAs 
were induced but Fam132b mRNA expression was unchanged (Supplementary Fig. 7).
ERFE-deficient mice have a transient hemoglobin deficit
Fam132b−/− mice were previously generated as part of a large-scale mouse knockout 
library19 and were reported to be viable and fertile without any abnormal phenotypic 
features. In our more detailed examination, Fam132b-deficient mice had mildly lower 
hemoglobin and mean corpuscular hemoglobin concentrations than wild-type mice at 6 
weeks of age (Fig. 4A, B), a time of rapid growth, erythropoietic expansion and high iron 
demand. Six week-old Fam132b+/− heterozygotes also exhibited slightly decreased 
hemoglobin levels compared to WT animals (Supplementary Fig. 8A). In contrast, 3, 12 and 
24 week-old Fam132b−/− mice had hematological parameters similar to those of wild-type 
mice. Fam132b−/− mice exhibited a trend toward lower mean corpuscular volume at 6, 12 
and 24 weeks, and lower serum iron level at 6 weeks, but the differences were not 
statistically significant (Supplementary Fig. 9)
We did not observe any baseline difference in liver iron or hepcidin between Fam132b+/+, 
Fam132b+/− and Fam132b−/− littermates at the ages examined (3, 6 and 24 weeks) 
(Supplementary Fig. 8 and 10). Spleen iron content was measured at 6 weeks of age and was 
also similar between wild-type and Fam132b−/− mice (Supplementary Fig. 8D).
ERFE is required for hepcidin suppression after blood loss
To determine whether ERFE is an erythroid regulator necessary for hepcidin regulation by 
increased erythropoietic activity, we studied hepatic hepcidin response to phlebotomy in 6 
week-old Fam132b+/+, Fam132b+/− and Fam132b−/− littermate mice. In contrast to the 
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rapid and profound suppression of hepcidin mRNA in Fam132b+/+ mice (10-fold 
suppression at 15 hours after phlebotomy), Fam132b-deficient mice failed to mount this 
response (Fig. 5A). Even Fam132b+/− mice showed a blunted suppression of hepcidin (~4-
fold) compared to their wild-type counterparts, consistent with lower levels of Fam132b 
mRNA expression in the bone marrow (Fig. 5B). After phlebotomy, serum iron 
concentrations in Fam132b−/− mice (but not in Fam132b+/+) were at all times significantly 
lower than baseline, consistent with the lack of suppression of hepcidin and a homeostatic 
defect in iron regulation after hemorrhage (Supplementary Fig. 11). These results support 
our hypothesis that ERFE is required for the regulation of hepcidin by increased 
erythropoietic demand. Flow cytometry analysis of bone marrow erythroblasts from 
Fam132b+/+ and Fam132b−/− littermate mice 72 hours after phlebotomy and in control mice 
did not reveal any difference in erythroblast differentiation (Supplementary Fig. 12) 
suggesting that ERFE is not necessary for erythroblast differentiation during baseline and 
stress erythropoiesis.
We next investigated whether ERFE facilitates compensatory iron acquisition during 
recovery from hemorrhage. Twelve week-old Fam132b+/+ and Fam132b−/− were 
phlebotomized and their hematological parameters monitored for 9 days. Throughout this 
period, ERFE-deficient mice exhibited lower hemoglobin, mean corpuscular hemoglobin, 
mean corpuscular volume and hematocrit levels compared to wild-type controls (Fig. 5C, D 
and Supplementary Fig. 13) demonstrating that the recovery of ERFE-deficient mice from 
hemorrhage-induced anemia was delayed by several days.
ERFE acts on the liver to suppress hepcidin
To test whether secreted erythroferrone protein is a suppressor of hepcidin, we injected 
C57BL/6 male mice with murine recombinant ERFE (2 μg/g body weight). We found that 
hepcidin mRNA and serum protein levels were significantly reduced 15 hours after ERFE 
treatment compared to saline-injected mice (Fig. 6A, B). despite a substantial inflammatory 
response (as shown by increased expression of Saa1 mRNA, Supplementary Fig. 14A), 
which would be expected to increase hepcidin. Using high performance gel-permeation 
chromatography under nondenaturing conditions, we confirmed a previous report16 that the 
purified recombinant protein had an effective molecular mass of 500–600 kDa suggesting 
that it was highly aggregated, a tendency shared by several other members of the TNFα 
superfamily. Measures that decrease aggregation may decrease the inflammatory effects of 
the recombinant protein and further increase its potency.
To avoid the acute inflammatory effect of the recombinant ERFE preparation, C57BL/6 
male mice were treated with a lentivirus-based vector encoding ERFE or a control vector 
(expressing GFP). Three weeks later, although we only achieved a modest increase in 
Fam132b mRNA in the liver (but not the bone marrow) (Fig. 6C), hepcidin mRNA and 
serum levels were reduced 30-fold and 10-fold respectively (Fig. 6D, E) suggesting that 
even a small amount of ERFE in the liver was sufficient to exert its inhibitory effect on 
hepcidin transcription. Saa1 mRNA was not increased in these mice (Supplementary Fig. 
14B). Neither recombinant ERFE nor chronic lentiviral expression of ERFE affected the 
BMP pathway, as measured by the expression of its canonical target Id1 mRNA 
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(Supplementary Fig. 14C,D). We then tested whether ERFE could act directly on the liver to 
regulate hepcidin. To circumvent recombinant ERFE aggregation and loss of potency during 
the purification process, mouse primary hepatocytes were treated for 15 hours with 50% 
(v/v) supernatants from control HEK293T cells or HEK293T cells overexpressing ERFE 
(Fig. 6F), resulting in a 4-fold decrease in hepcidin mRNA levels in ERFE-treated cells (Fig. 
6G). Taken altogether, these results show that ERFE is a potent suppressor of hepcidin that 
can act directly on the liver to repress hepcidin mRNA expression.
Mice with β-thalassemia intermedia have high levels of ERFE
HbbTh3/+ mice are an established model of β-thalassemia intermedia, and exhibit anemia, 
ineffective erythropoiesis and splenomegaly20. Their hepatic hepcidin expression is 
inappropriately low, leading to hyperabsorption of iron and hepatic iron overload20. We 
assayed Fam132b mRNA in the marrow and spleen of 6-week-old HbbTh3/+ mice. As 
expected, the mice were anemic and had very high serum EPO concentrations (Fig. 7A, B). 
Compared to their WT littermates, Fam132b mRNA levels in HbbTh3/+ mice were increased 
10-fold in the bone marrow and 16-fold in the spleen (Fig. 7C) suggesting that ERFE may 
be involved in hepcidin dysregulation in β-thalassemia. Ablation of ERFE in β-thalassemic 
mice (Fam132b−/−HbbTh3/+) raised hepcidin levels (Fig. 7D) and decreased hepatic iron 
overload compared to HbbTh3/+ mice (Fig. 7E). Consistent with the expected effect of 
increased hepcidin levels in Fam132b−/−HbbTh3/+ mice, serum iron concentrations and 
erythrocyte MCV and MCH were also decreased compared to HbbTh3/+ mice 
(Supplementary Fig. 15). Thus, ERFE contributes to hepcidin suppression and iron overload 
in this model of β-thalassemia intermedia.
DISCUSSION
The search for the erythroid regulator of iron homeostasis that assures adequate iron supply 
for increased erythropoietic activity has been ongoing for many years1. Discovery of the 
iron regulatory hormone hepcidin and its suppression in anemia suggested a mechanism. It 
was proposed that hepcidin suppression in anemias may result from direct hepcidin 
regulation by hepatocellular hypoxia3, 21 or erythropoietin3, 22. However, later studies 
provided convincing evidence against a biologically-important direct effect of hypoxia on 
hepcidin transcription23. The lack of hepcidin suppression after bleeding or EPO injections 
in mice with ablated bone marrow 4, 5, 23 also argues against a direct effect of hypoxia or 
EPO. Rather, these studies suggest that high levels of EPO cause hepcidin suppression 
indirectly, by inducing the secretion of erythroid regulators from the bone marrow which, in 
turn, act on the liver to suppress hepcidin expression and increase iron delivery from dietary 
absorption and stores. We therefore initiated a search by a gene-expression microarray for a 
potential hepcidin suppressor, highly induced in the bone marrow prior to hepcidin 
suppression in the liver (Fig. 1). We focused on secreted proteins whose mRNA expression 
was rapidly increased 4 hours after phlebotomy or EPO injection, and identified the orphan 
TNF-α superfamily member Fam132b as a new erythroid regulator secreted by 
differentiating erythroblasts (Fig. 2, 3). We named this factor erythroferrone as our results 
suggest it functions as a hormone linking erythropoiesis and iron metabolism (Fig. 8). In 
gene expression databases, FAM132B was highly expressed in the bone marrow and fetal 
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liver, and an in vitro study of differentiated human erythroblasts24 reported that FAM132B 
expression was highest in intermediate erythroblasts. We documented the high expression of 
Fam132b mRNA in mouse and human erythroblasts and established that it is greatly 
induced by erythropoietic stimulation (Fig. 3 and Supplementary Fig. 5) but not directly 
affected by hypoxia-related or inflammatory stimuli (Supplementary Fig. 6 and 7). In the 
meantime, another study reported that Fam132b (also termed myonectin or CTRP15) is 
generated predominantly in skeletal muscle, is suppressed by fasting and induced by 
refeeding, and participates in the regulation of systemic lipid metabolism16. The study, 
however, did not include analysis of the bone marrow. Further work will be needed to 
understand how these distinct activities coexist and to assess their respective biological and 
pathological relevance.
In the absence of ERFE, the mechanism suppressing hepcidin early after erythropoietic 
stimulation is abrogated and Fam132b-deficient mice exhibit several days delay in recovery 
from hemorrhage compared to wild-type animals (Fig. 5). This confirms that ERFE is a 
biologically important regulator of hepcidin expression and is required for the rapid 
compensatory response to hemorrhage. Nevertheless, Fam132b-deficient mice do recover 
from hemorrhage suggesting that other mechanisms eventually increase iron availability for 
new erythrocyte synthesis. This is not surprising as recovery from hemorrhage is subject to 
strong evolutionary pressure, and likely mediated by multiple mechanisms. Even if hepcidin 
is not suppressed rapidly, increased iron demand from accelerated erythropoiesis could 
eventually cause transient iron deficiency (i.e. decreased plasma iron concentration) which 
would be expected to decrease hepcidin levels and therefore increase iron absorption and 
release from the stores. Interestingly, mature Fam132b-deficient mice at baseline do not 
exhibit any detectable abnormalities as their iron parameters and hepcidin expression are 
similar to wild-type controls (Supplementary Fig. 8, 9, 10 and 12). Moreover, the induction 
of Fam132b mRNA after blood loss was not modulated by the BMP/Smad pathway or iron 
(Supplementary Fig. 3D). Thus, ERFE is a stress erythropoiesis-specific regulator, and does 
not play a major role in baseline erythropoiesis. Consistent with this, ERFE ablation in mice 
only causes a transient deficit in hemoglobin synthesis as erythropoiesis intensifies during 
rapid growth between 3 and 6 weeks of age (Fig. 4). The strong dependence of Fam132b 
induction by EPO on the Stat5 pathway (Fig. 3C) is also consistent with a role in stress 
erythropoiesis.
In mice, the injection of recombinant ERFE, or ERFE over-expression using lentiviral 
vectors confirmed that ERFE is an effective suppressor of hepcidin in vivo (Fig. 6). 
Treatment of primary hepatocytes with ERFE demonstrated that the hormone exerts its 
hepcidin-suppressive activity directly on hepatocytes (Fig. 6G). Further work is needed to 
identify ERFE’s receptor(s) and the downstream effectors controlling hepcidin expression. 
The BMP/Smad signaling pathway, the principal pathway mediating iron-dependent 
regulation of hepcidin, may not be involved in ERFE-mediated hepcidin regulation as 
neither HJV nor TfR2 were necessary for rapid hepcidin suppression after blood loss 
(Supplementary Fig. 3), Smad5 phosphorylation was not decreased (Supplementary Fig. 
2A–D), and Id1, a canonical target of the BMP pathway, was not appreciably affected by 
erythropoietic stimulation (Supplementary Fig. 2E) or ERFE treatment (Supplementary Fig. 
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14). Thus, although both the iron-regulated BMP/Smad pathway and erythropoietin-
regulated ERFE pathway converge on hepcidin, we saw no significant evidence of crosstalk 
between them. Hemorrhage/ERFE-mediated suppression of hepcidin mRNA was observed 
over a large range of iron loads and baseline hepcidin mRNA concentrations, and the ERFE 
signal appeared to act on the hepcidin gene independently from the iron-regulated BMP/
Smad pathway. A recent study of hepcidin regulation by iron in an Epo-overproducing 
mouse model25 also supports the existence of independent pathways regulating hepcidin in 
response to hepatic iron load and erythropoietic activity.
Hepcidin suppression by increased erythropoietic activity underlies the development of iron 
overload in inherited anemias with ineffective erythropoiesis. This is particularly evident in 
untransfused patients26, 27 where hyperabsorption of dietary iron is the sole source of iron 
overload. Studies of human patients will be necessary to establish whether ERFE plays a 
role in hepcidin suppression and iron overload in anemias with ineffective erythropoiesis. 
The production of ERFE would be expected to increase in iron-loading anemias with 
ineffective erythropoiesis, considering that these patients have high EPO levels and 
massively expanded erythroblast populations28. Indeed, our measurements in the mouse 
model of β-thalassemia intermedia (Fig. 7C) document a large increase in Fam132b mRNA 
expression in the marrow and spleen. Ablation of Fam132b in a mouse model of β-
thalassemia intermedia reverses the hepcidin defect, and decreases hepatic iron overload 
(Fig. 7D and E), serum iron concentrations and erythrocyte MCV and MCH (Supplementary 
Fig. 15). Thus, erythroferrone is a strong candidate for a pathological hepcidin suppressor in 
inherited anemias with ineffective erythropoiesis, where hepcidin levels are inversely 
correlated with EPO concentrations and erythropoietic activity29, 30. Although the changes 
induced by ERFE ablation are smaller and do not affect blood hemoglobin concentrations, 
the pattern is otherwise similar to the effect of pharmacologic increases of hepcidin 
expression in β-thalassemic mice31–33. If the contribution of ERFE to hepcidin suppression 
and iron overload in iron-loading anemias is confirmed in clinical studies, ERFE 
neutralization would be a rational and apparently specific therapeutic strategy. At the other 
end of the disease spectrum, the ability of ERFE to suppress hepcidin could be useful in the 
treatment of iron-restrictive anemias characterized by increased hepcidin, including anemia 
of inflammation, anemia of chronic kidney diseases and iron-refractory iron-deficiency 
anemia. 34
METHODS
Mice
Experiments were conducted in accordance with guidelines by the National Research 
Council and were approved by the University of California, Los Angeles. Wild type (WT) 
C57BL/6J males were purchased from The Jackson Laboratory (Bar Harbor, Me). 
Tfr2Y245X/Y245X (FVB background35, from Dr. Robert Fleming, Saint Louis University, 
MO) and Hjv−/−(129S6/SvEvTac background36, from Dr. Paul Schmidt, Children’s Hospital 
Boston, MA) mutant mice were maintained at UCLA. Fam132b+/− mice on a mixed Sv129/
C57BL/6 background (Fam132btm1Lex) were generated by Lexicon Pharmaceuticals19 by 
deletion of 3204bp of the genomic sequence (exons 2–7) and insertion of a neomycin 
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cassette and were obtained from the Mutant Mouse Regional Resource Center (MMRRC) at 
UC Davis (strain B6;129S5-Fam132btm1Lex/Mmucd, ID MMRRC:032289-UCD). 
Fam132b+/− mice were crossed to generate Fam132b+/+, Fam132b+/− and Fam132b−/− 
littermates that were maintained at UCLA. Hbbth3/+ mice were obtained from The Jackson 
Laboratory (strain name B6;129P-Hbb-b1tm1Unc Hbb-b2tm1Unc/J) and maintained at UCLA 
in heterozygosity by breeding with C57BL/6 mice. Unless otherwise specified, mice 
received a standard diet (NIH 31 rodent diet, 336 ppm iron, Harlan Teklad, Indianapolis, IN) 
and were analyzed between 6 and 8 weeks of age. A set of Tfr2Y245X/Y245X (Tfr2 ko ID) 
were fed an iron-deficient diet containing 4 ppm iron (Harlan Teklad, TD 80396) at weaning 
and were studied at 6 weeks of age. Fam132b+/+, Fam132b+/− and Fam132b−/− mice were 
analyzed at 3, 6, 12 and 24 weeks of age. To provide an erythropoietic stimulus, mice were 
phlebotomized by retro-orbital puncture (500 μL) or treated with a single dose of 200 units 
human erythropoietin (Epogen, Amgen), and analyzed within 24–48 hours. For the studies 
of recovery from anemia, Fam132b+/+ and Fam132b−/− mice were monitored for 9 days 
after a 500 μL phlebotomy and 25–50 μL of blood were collected by retro-orbital puncture at 
each time-point for hematological parameters assessment. In some experiments, C57BL/6 
males were given 2 doses of 25 mg iron-dextran (Sigma-Aldrich) in two consecutive weeks 
and were phlebotomized and analyzed a week later at the age of 7 weeks. HbbTh3/+ mice 
were mated with Fam132b−/− to generate Fam132b+/−, HbbTh3/+ mice and subsequent 
breeding of these mice to Fam132b+/− mice generated littermates wild-type, HbbTh3/+ and 
Fam132b−/−, HbbTh3/+ (referred to as Fam132b−/−Th3/+) that were maintained at UCLA 
on an iron-balanced diet containing 50 ppm diet (Harlan Teklad, TD 06015) and studied at 
the age of 6 weeks.
Measurement of iron and hematologic parameters
Serum iron, spleen and liver non-heme iron concentrations were determined as previously 
described37, using acid treatment followed by a colorimetric assay for iron quantitation 
(Sekisui Diagnostics, Charlottetown, Canada). Complete blood counts were obtained with a 
HemaVet blood analyzer (Drew Scientific).
Microarray analysis
Total RNA from mouse bone marrow was extracted using Trizol (Invitrogen) and purified 
using RNeasy Micro kit (Qiagen). RNA quality was checked on RNA 6000 Nano chips 
using a Bioanalyzer 2100 (Agilent Technologies). Gene-level expression profiling of the 
bone marrow after phlebotomy was performed with the GeneChip® Gene 1.0 ST Array 
System for mouse (Affymetrix). Expression data were analyzed using the GeneSpring 
software (Agilent) by comparing control mice (n=3) to mice at the time-points 4h (n=1 to 
indicate stress-related variations of transcription), 9h (n=3), 12h (n=2), 15h (n=2) and 48h 
(n=2).
Quantitation of mRNA levels
Total RNA from mouse tissues was extracted using Trizol (Invitrogen). Total RNA from 
muscle, heart and brain was extracted using RNeasy fibrous tissue mini kit (Qiagen). cDNA 
was synthesized using iScript (Biorad). Quantitative PCR reactions were prepared with Sso 
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advanced Sybr Green supermix (Biorad) and primers indicated in Supplementary Table 2, 
and run in duplicate on a CFXconnect Instrument (Biorad). Hamp, Fam132b, Id1, Saa1 and 
Gypa mRNA transcript abundance was normalized to the reference genes Hprt or Rpl4. 
Results are expressed as −ΔCt ± standard error of the mean (i.e., the cycle threshold 
differences between reference and target genes within each group of mice). Expression ratio 
and SEM values of Hamp transcripts in ERFE-treated cells relative to controls and 
normalized to the reference gene Hprt mRNA was calculated using REST38. Statistical 
significance was determined using randomization tests.
Isolation of human erythroblasts
CD34−/CD235+ cells from fetal livers were sorted by Novogenix Laboratories, LLC as 
previously described39 from de-identified specimens following informed consent. CD34−/
CD235+ human bone marrow cells were a kind gift of Dr. Gay Crooks (Departments of 
Pathology & Laboratory Medicine and Pediatrics in the David Geffen School of Medicine, 
UCLA).
Rapid Amplification of cDNA Ends (RACE)
Human fetal liver erythroblasts obtained from Novogenix Laboratories, LLC., were 
resuspended in IMDM medium (GIBCO) supplemented with 20% FBS and 2mM L-
Glutamine (Invitrogen) and treated 15 hours with 10U/mL of erythropoietin (Epogen, 
Amgen). Total RNA was extracted using Trizol (Invitrogen) and purified using RNeasy 
Micro kit (Qiagen). 5′ RACE was performed using Generacer (Invitrogen) according to the 
manufacturer’s instructions.
Mouse bone marrow erythroblasts isolation and treatment
Freshly isolated total bone marrow cells from C57BL/6 mice femurs were suspended in 
IMDM medium (GIBCO) supplemented with 20% FBS and 2mM L-Glutamine (Invitrogen). 
Cells were pre-treated for 2 hours with two different Stat5 inhibitors: 10 μM pimozide 
(Sigma) or 200 μM N′-((4-Oxo-4H-chromen-3-yl)methylene)nicotinohydrazide 
(Calbiochem) and incubated overnight (15h) with 10 U/mL of human recombinant 
erythropoietin (Epogen, Amgen). Treatments were done in duplicates in three independent 
experiments. To test the effect of hypoxia, mouse erythroblasts were treated overnight (15h) 
with 1mM DMOG (Dimethyloxalylglycine, N-(Methoxyoxoacetyl)-glycine methyl ester, 
SIGMA).
Fluorescence-Activated Cell Sorting
To isolate erythroblasts at different stages of maturation by cell sorting, >15 × 106 bone 
marrow cells from six 7 week-old Sv129/C57BL/6 Fam132b+/+ littermate mouse femurs 
(three controls and three 15 hours after phlebotomy) were filtered through a 30 μm filter and 
resuspended in 1 mL PBS/5% FCS. Cells were blocked with rat anti-mouse CD16/CD32 
(0.25 μL/106 cells, BD Biosciences no. 553142) for 15 minutes and subsequently stained 
with FITC rat anti-mouse TER-119 (0.5 μL/106 cells, BD Biosciences no. 557915), and PE 
rat anti-mouse CD71 (0.5 μL/106 cells, BD Biosciences no. 553267) and incubated on ice 
for 30 minutes in the dark. Cells were washed twice with 1 mL PBS and resuspended in 2 
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mL PBS/5%FCS. Sorting was performed on a FACSAriaII High-Speed Cell Sorter (Becton 
Dickinson). Erythroblasts population were differentiated as previously described17 into four 
populations: pro-erythroblasts (pro-E, Ter119med CD71high FSChigh), basophilic 
erythroblasts (Ter119high CD71high FSChigh), polychromic erythroblasts (Ter119high 
CD71high FSClow) and orthochromic erythroblasts (Ter119high CD71low FSClow).
Construction of the ERFE-secreting cell line
Lentivirus-based vectors pRRL-sin-cPPT-hCMV-MCS-IRES-emdGFP encoding ERFE 
mouse cDNA ORF (accession number NM_173395) fused to a C-terminal 3xFLAG tag and 
empty control vector were produced by the UCLA Vector Core facility. Internal ribosome 
entry site ensured reinitiation and translation of Green Fluorescent Protein (GFP). Vector 
titers were determined by p24 ELISA (Perkin Elmer). HEK293T cells (ATCC® 
CRL-3216™) were transduced using 4 μg/ml Polybrene (Sigma, H9268). Insertion of the 
virus was confirmed by GFP detection by fluorescence microscopy. ERFE overexpression 
and secretion was monitored by western blot.
Recombinant protein production and purification
Supernatants from HEK293T overexpressing FLAG-tagged ERFE were harvested after 5 
days, supplemented with protease inhibitor cocktail and purified using an anti-FLAG 
affinity gel according to the manufacturer’s protocol (Sigma) and eluted with 150 μg/ml 
FLAG peptide (Sigma). FLAG peptide was then eliminated by filtration through Amicon 
Ultra 30K device (Millipore) and recombinant ERFE was resuspended in saline (0.9% 
NaCl). Protein concentration was determined by Coomassie Imperial Protein Stain (Pierce) 
and bicinchoninic acid protein assay (Pierce).
Western blot analysis
Supernatants from ERFE-secreting HEK293T cells were subjected to SDS-PAGE and 
electroblotted to PVDF membranes (Biorad). Membranes were incubated with an anti-DDK 
monoclonal antibody (4C5, Origene) which recognizes DYKDDDDK epitope (FLAG-Tag) 
using the ONE-HOUR Western™ Detection System (Genscript) following manufacturer’s 
instructions. For Smad5 analysis, membranes were incubated with phospho-Smad5 
(Ser463/465, Abcam, ab92698) and Smad5 (Epitomics, 1682-1) antibodies, as previously 
detailed40 and with GAPDH (Cell Signaling Technology, 14C10). Western blots were 
visualized by chemiluminescence using the ChemiDoc XRS+ imaging system with Image 
Lab software (Bio-Rad).
Enzyme-linked immunosorbent assays
Mouse hepcidin-1 monoclonal antibodies, Ab2B10 (capture), AB2H4-HRP (detection) and 
synthetic mouse hepcidin-25, were a generous gift from Amgen (Thousand Oaks, CA) 41. 
High binding 96-well EIA plates (Corning) were coated overnight at room temperature with 
50 μL/well of 3.6 μg/mL Ab2B10 in 0.2 M carbonate-bicarbonate buffer pH 9.4 (Pierce). 
Plates were washed twice with wash buffer (PBS, 0.5% Tween-20) and blocked for 45 
minutes with 200 μL/well blocking buffer (PBS, 1% BSA, 1% normal goat serum, 0.5% 
Tween-20). Samples and standards were added and incubated 1 hour at room temperature. 
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After four washes, plates were incubated an hour with 50 μL/well of 130 ng/mL Ab2H4-
HRP, washed 4 times then developed with 100 μL/well Ultra-TMB substrate (Thermo 
Scientific) for 30 minutes in the dark at room temperature. The reaction was stopped by 
adding 50 μL 2M sulfuric acid and the absorbance was measured at 450 nm. Serum Epo was 
measured using mouse Epo quantikine set (R&D Systems), according to the manufacturer’s 
instructions.
Recombinant protein injection
Recombinant ERFE (2 μg/g of body weight) or the equivalent volume of saline solution 
(0.9% NaCl) was injected intraperitoneally into 8 week-old C57BL/6 mice (n=6). To 
prevent any interference by dietary iron overload, mice were placed on iron-deficient diet 
(4ppm Fe) 10 days prior to the injection. Mice were analyzed 15 hours after treatment.
Mouse primary hepatocyte isolation and treatment
Hepatocytes were isolated from wild-type C57BL/6 mice by a two-step portal vein 
collagenase perfusion method as previously described42 and incubated overnight (15 hours) 
in fresh Williams E Medium (Sigma Aldrich) supplemented with 5% FBS and 200 μM L-
glutamine (Invitrogen) and 50% (v/v) supernatants from control HEK293T cells or 
HEK293T cells overexpressing ERFE (also maintained in Williams E Medium/5%FBS/200 
μM L-glutamine). Three independent experiments with 15 hour treatments in triplicate were 
performed.
Injection of lentiviral vector
Lentiviral vector supernatants were thawed and diluted in 0.9% saline. Six week-old 
C57BL/6 mice were injected intravenously with 1 × 108 IU of a control lentiviral vector or 
the lentiviral vector encoding ERFE (200 μL injection volume). Mice were analyzed three 
weeks after injection.
Statistical analysis
The statistical significance of differences between groups was evaluated using Sigmaplot 
11.0 package (Systat Software, San Jose, CA). The Student t test was used to compare 2 
groups of normally distributed data. The Mann Whitney rank-sum test was used to compare 
data that were not normally distributed. A P value < 0.05 in a two-tailed test was considered 
as statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Time-course of hepcidin mRNA and protein concentrations after phlebotomy (500 μL) 
or treatment with erythropoietin (EPO, 200 U)
(A) Hamp mRNA levels were reduced within 9 hours and maximally suppressed 12–15 
hours after phlebotomy (solid line) or treatment with EPO (dashed line). (B) Serum hepcidin 
levels after phlebotomy and treatment with EPO reflect mRNA concentrations. Both graphs 
show means ± SEM. Log2 hepcidin mRNA concentration relative to that of a housekeeping 
gene Hprt, −ΔCt (i.e., Ct Hprt – Ct Hamp) is shown as measured by qRT-PCR and serum 
hepcidin values were obtained by enzyme-linked immunosorbent assay. Each time-point 
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was compared to the control mice (t=0) by two-tailed Student t-test (n=4 mice per point). 
***p<0.001, **p<0.01, *p<0.05 for phlebotomy, ###p<0.001, ##p<0.01, #p<0.05 for EPO 
treatment.
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Figure 2. Induction of ERFE-encoding Fam132b mRNA after phlebotomy (500 μL) or treatment 
with erythropoietin (EPO, 200 U)
Fam132b mRNA in the bone marrow (A) and the spleen (B) of 6 week-old C57BL/6 wild-
type males is rapidly increased 4–9 hours after phlebotomy (solid line) or EPO treatment 
(dashed line). Means of −ΔCt (i.e., Ct Hprt – Ct Fam132b) ± SEM are shown as measured 
by qRT-PCR, and compared for each time-point to the t=0 control by two-tailed Student t-
test (n=4). ***p<0.001, **p<0.01, *p<0.05 for phlebotomy, ###p<0.001, ##p<0.01, #p<0.05 
for EPO treatment.
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Figure 3. ERFE is produced in erythroblasts and induced by erythropoietic stimuli through the 
Jak2/Stat5 signaling pathway
(A) Tissue-specific expression of Fam132b mRNA. Fam132b mRNA expression was 
stimulated only in the bone marrow and in the spleen of 6 weeks-old C57BL/6 mice 15 
hours after 200 U EPO treatment (n=6). (B) Fam132b mRNA expression across stages of 
erythroblast development from proerythroblasts (Pro-E) through basophilic (baso), 
polychromatic (poly) to orthochromatic (ortho) erythroblasts. Fam132b mRNA was 
measured by qRT-PCR in erythroid cells isolated from the bone marrows of three controls 
and three phlebotomized (15 h) 6 week-old C57BL/6 mice. Cells were sorted by size and 
anti-Ter119 and anti-CD71 staining18. (C) Fam132b induction by EPO is dependent on 
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Stat5. Stimulation of Fam132b mRNA expression in erythroblasts by EPO treatment (15 h, 
10 U/mL) was inhibited by Stat5 inhibitors pimozide (10 μM) or N′-((4-Oxo-4H-chromen-3-
yl)methylene)nicotinohydrazide (200 μM). Erythroferrone (Fam132b) mRNA levels were 
measured by qRT-PCR. Values shown are means ± SEM of −ΔCt (i.e., Ct Hprt or Rpl4 – Ct 
Fam132b). Means of −ΔCt values were compared between control and erythropoietic 
stimulation by two-tailed Student t-test (A, B). Bonferroni correction was applied to the 
multiple comparisons represented in panel A. (C) Expression ratio ± SEM of Fam132b 
transcripts in EPO-treated cells relative to controls and normalized to the gene Gypa mRNA 
was calculated using REST. Normalization by glycophorin A allowed the normalization of 
Fam132b mRNA expression per red cell. Results of 3 independent experiments with 15 hour 
treatments in duplicate are shown. Statistical significance was determined using 
randomization tests. ***p<0.001, **p<0.01
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Figure 4. At 6 weeks of age, ERFE-deficient mice have lower hemoglobin and mean corpuscular 
hemoglobin (MCH) levels than wild type mice
Hemoglobin and MCH were compared between Fam132b+/+ and Fam132b−/− littermates at 
the ages of 3, 6, 12, and 24 weeks. Values shown are means of hemoglobin or MCH ± SEM. 
Means were compared between genotypes by two-tailed Student t-test (n=8 to 16 mice per 
time point and genotype). ***p<0.001, **p<0.01, *p<0.05.
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Figure 5. Fam132b-deficient mice do not suppress hepcidin in response to phlebotomy and show 
delayed recovery from anemia
(A) After phlebotomy, hepatic Hamp mRNA expression was measured in Fam132b+/+ 
(dashed line), Fam132b+/− (dotted line) and Fam132b−/− (solid line) littermates (n=6 to 14 
per genotype and time-point). Hepcidin is suppressed after hemorrhage in wild-type mice 
but not in Fam132b-deficient mice, with Fam132b+/− presenting an intermediate response 
between the wild-types and knockouts. (B) After phlebotomy, both Fam132b+/+ (dashed 
line) and Fam132b+/− (dotted line) mice increase Fam132b mRNA expression in the bone 
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marrow, although the maximal levels were about twice as high in Fam132b+/+ compared to 
Fam132b+/−. (C and D) Phlebotomized Fam132b-deficient mice (solid line) compared to 
wild-type mice (dashed line) showed delayed recovery of hemoglobin and lower mean 
corpuscular hemoglobin (MCH). Hepcidin (Hamp) (A) and Fam132b (B) mRNA levels 
were measured by qRT-PCR and shown as −ΔCt (i.e., Ct Hprt – Ct Hamp or Fam132b). For 
each genotype, means of −ΔCt values were compared at each time-point to the respective 
control mice t=0 by two-tailed Student t-test. Hematological parameters (C, D) were 
compared for each measurement between WT (n=17) and KO (n=15) by Student t-test. All 
graphs show means ± SEM. In the absence of gender differences, the genders were 
combined for each parameter. ***p<0.001, **p<0.01, *p<0.05
Kautz et al. Page 23
Nat Genet. Author manuscript; available in PMC 2015 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 6. ERFE acts directly on the liver to suppress hepcidin
(A, B, C) Six C57BL/6 male mice were treated intraperitoneally with either mouse 
recombinant ERFE (2 μg/g) or saline and analyzed 15 hours later. Hepatic hepcidin mRNA 
(A) and serum hepcidin (B) levels were significantly suppressed by ERFE treatment. (C, D, 
E) Seven week-old C57BL/6 males were transduced with a lentivirus encoding GFP or 
mouse ERFE (n=8 per group) and analyzed after 3 weeks. (C) Fam132b mRNA expression 
was not detectable (ND) in the liver of control mice, and was moderately increased in the 
liver of mice transduced with the ERFE lentivirus although only 2-fold higher than the 
baseline bone marrow levels. However, this increase was sufficient to significantly reduce 
hepatic hepcidin mRNA (D) and serum hepcidin (E) levels. (F) Recombinant mouse ERFE 
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is secreted by HEK293T cells infected with the ERFE-lentivirus, as detected by Western 
blot with an anti-FLAG antibody. (G) Treatment of mouse primary hepatocytes with 
supernatants (50% v/v) from HEK293T control cells or HEK293T cells overexpressing 
ERFE indicated that ERFE acts directly on the liver to suppress hepcidin mRNA expression. 
Hepcidin (Hamp), serum amyloid 1 (Saa1) and ERFE (Fam132b) mRNA levels were 
measured by qRT-PCR and are shown as −ΔCt (i.e., Ct Hprt – Ct Hamp, Saa1 or Fam132b). 
Graphs show means± SEM. Mean values were compared between treated mice and control 
mice or between ERFE-treated to control samples by two-tailed Student t-test. ***p<0.001, 
**p<0.01, *p<0.05
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Figure 7. In a mouse model of β-thalassemia intermedia, erythroferrone is markedly increased, 
suppresses hepcidin and contributes to iron overload
Six week-old HbbTh3/+ mice had (A) lower hemoglobin and (B) greatly increased serum 
Epo concentrations compared to their wild-type littermate mice (n=7 mice per genotype). 
Fam132b mRNA expression (C) was highly increased in the bone marrow and the spleen of 
HbbTh3/+ mice compared to wild-type controls. (D and E) Comparing six week-old 
littermates WT (n=12), HbbTh3/+ (n=12) and Fam132b−/−HbbTh3/+ (n=18), ablation of 
ERFE reversed hepcidin suppression (D) and significantly decreased hepatic iron overload 
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(E). Values shown are means ± SEM. Statistical comparisons were performed by two-tailed 
Student t-test for normally distributed variables and Mann-Whitney rank sum test otherwise. 
***p<0.001, **p<0.01, *p<0.05.
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Figure 8. Proposed role of the erythroid factor erythroferrone (ERFE)
After erythropoietic stimulation, differentiating erythroblasts in the bone marrow and spleen 
rapidly increase ERFE production in an EPO-Stat5 dependent manner. ERFE is secreted into 
the circulation and acts directly on the liver to repress hepcidin. ERFE-mediated hepcidin 
suppression in turn increases iron availability for new red blood cells synthesis.
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